Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Raises Price Target to $3.5

Benzinga Newsdesk www.benzinga.com Positive 69.5%

Neg 0% Neu 0% Pos 69.5%

Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and raises the price target from $2.5 to $3.5.